Introduction
Interleukin-17 (IL-17) was originally isolated from an activated T-cell hybridoma in 1993 [1] , and consists of an interleukin family with five other members (IL-17B-F) that had been identified subsequently [2] [3] [4] . IL-17 is mainly secreted by T H 17 lymphocytes, a novel subset of CD4 + T helper cells that play a pivotal role in mediating autoimmunity and inflammation [5] [6] [7] [8] [9] [10] [11] [12] . These T H 17 lymphocytes have been shown to contribute to the pathogenesis of several autoimmune and inflammatory diseases, such as experimental autoimmune encephalitis (EAE) and collagen-induced arthritis (CIA) [7, 8] , and consistent with this suggestion, IL-17-deficient mice are resistant to EAE and CIA [13] . IL-17 treatment primarily induces the expression of three classes of genes: (a) cytokines/chemokines, including IL-6, IL-8, CXCL1, CXCL2, CXCL5, CCL2, CCL5, CCL7 and CCL20; (b) cytoplasmic proteins involved in the immune response/ inflammation, including LCN2/24p3, COX2 and EREG; and (c) extracellular matrix/adherence proteins, including Mmp3, Mmp9, Mmp13 and ICAM-1 [2-4, 10, 14, 15] (also see review [16] ). Recently, IL-17 was reported to induce the expression of RGD13 and RGS16, which, together with Cxcr4, regulate B-cell differentiation [17] . IL-17 also induces high levels of hBD-2 and IL-19 expression in human airway epithelial cells [18] . As IL-17 signaling is operative in many tissues, such as the brain, lung, articular cartilage, bone and intestine [2] [3] [4] , it is clear that a major role of IL-17 is to regulate the cytokine network and provide a link between T H 17 lymphocyte activation and the homeostasis of other tissues in health and disease.
IL-17 receptor (IL-17R or IL-17RA) is the founding member of the IL-17R family, which consists of five members, which have been known as IL-17RA-E to date [2] [3] [4] . Mice deficient in IL-17R fail to respond to IL-17 [19, 20] , and soluble IL-17R or antibodies against IL-17R block the activity of IL-17 in human epithelial cells [21] , showing that IL-17R is essential for IL-17 signaling.
At the time of discovery, IL-17 and IL-17R appeared striking in their uniqueness. IL-17 and IL-17R showed no clear similarity to any other known interleukin or cytokine receptor, nor did they even contain a known recognizable protein domain [4] . Thus, the IL-17 system seems to be a distinct signaling system differing from those of the other interleukins, explaining why IL-17 signaling cascades have remained elusive even after more than 10 years since their discovery. Recently, the identification of IL-17F and the analysis of its crystallographic structure have revealed that the homodimeric cytokines IL-17 and IL-17F share a similar structural feature with the cystine-knot growth factor family, suggesting that IL-17 may have a relationship with these growth factors [22] . The cystine-knot growth factor superfamily is quite diverse, consisting of bone morphogenetic proteins (BMPs), transforming growth factor beta (TGF-b), platelet-derived growth factors (PDGFs), nerve growth factor (NGF) and other neurotrophins [23] . Members of the cystineknot growth factor superfamily function as a homodimer and bind both homodimeric and heteromeric receptors during signal transduction [23, 24] . On the basis of the structural information and the shared binding features with cystine-knot growth factors, we speculated that IL-17 might signal through a heteromeric receptor complex. This hypothesis has been supported by the recent finding that IL-17RC is an essential component of the IL-17R signaling complex [19] .
Subsequent to the discovery of IL-17RD (Sef), a SE-FIR domain (after Sef and IL-17R's) was identified in transmembrane IL-17R's as well as other soluble factors such as Act1 [25] . Interestingly, it was recently reported that Act1 and IL-17R exhibit homotypic association mediated by the SEFIR domain and that Act1 functions as an adaptor to mediate IL-17 signaling [26, 27] . In this study, we show that IL-17RD (Sef), an orphan receptor member of the IL-17R family earlier identified by our group and others [28] [29] [30] [31] [32] [33] , interacts with IL-17R and mediates IL-17 signaling. Our results provide novel evidence that IL-17 signals through a heteromeric and/or homomeric receptor complex that includes IL-17RD.
Results

IL-17RD associates with IL-17R
To identify additional members of the IL-17R family, we screened the National Center for Biotechnology Information (NCBI) database using the intracellular domain of IL-17R and cloned two isoforms of IL-17RD, IL-17RLM-L (Sef) and IL-17RLM-S (Sef-S) [29, 31] .
We noted that IL-17RD (Sef), IL-17R and Act1 share the SEFIR domain [25] . Recently, Act1 has been shown to homotypically interact with IL-17R, mediated by the SE-FIR domain, and to function as an adaptor protein for IL-17 signaling [26, 27] . We therefore speculated that IL-17RD might also associate with IL-17R and mediate IL-17 signaling.
To test this hypothesis, we first examined whether IL-17RD interacts with IL-17R in cultured cells. When IL-17RD and IL-17R were co-expressed in HEK293T cells, IL-17R was immunoprecipitated with IL-17RD and IL-17 treatment did not enhance this association ( Figure  1A) . We further examined the interaction between the endogenous IL-17R and IL-17RD by precipitating the receptor complex with either anti-IL-17R or anti-IL-17RD antibody in either MEF or NIH3T3 cells. The results showed that the anti-IL-17R antibody co-precipitated the endogenous IL-17RD protein and vice versa ( Figure 1B ). Our data also indicate that the interaction of endogenous IL-17R with IL-17RD does not respond to IL-17 stimulation as there was no significant change in the intensity of the interaction in the presence or absence of IL-17 in both cell lines ( Figure 1B , compare lanes 2 with 3, and 5 with 6). Immunoprecipitation experiments using extracts with or without overexpression of IL-17R or IL-17RD consistently indicate that IL-17R interacts with IL-17RD independently of IL-17 stimulation.
In addition, we used rabbit anti-IL-17RD serum to immunoprecipitate endogenous IL-17RD in HEK293T cells and showed the presence of IL-17R-Myc protein in the precipitated complexes ( Figure 1C , lane 2). When IL-17RD was co-expressed, a greater amount of IL-17R-Myc protein was co-precipitated ( Figure 1C , lane 5 compared with lane 2), suggesting that both the endogenous IL-17RD and the overexpressed IL-17RD proteins associate with the IL-17R-Myc protein. Interestingly, we also found that IL-17RD interacts with IL-17RB ( Figure 1C , lanes 3 and 6). Furthermore, we generated two mutants of IL-17RD, IL-17RDDECD and IL-17RDDICD, which lack the extracellular domain (ECD) and the intracellular domain (ICD), respectively. Immunoprecipitation assay results with these mutants show that they are able to interact with IL-17R ( Figure 1D ), suggesting that the ECD or ICD alone is sufficient to establish an association between IL-17RD and IL-17R. These data also indicate that the association between these two molecules is not mediated only by SEFIR domain homotypic interaction, but that other domains may also contribute to the interactions.
IL-17RD colocalizes with IL-17R
Given that IL-17RD interacts with IL-17R, we further examined whether these two molecules colocalize within the cell. For this, we co-expressed Myc-tagged IL-17RD and HA-tagged IL-17R in COS7 cells and carried out immunostaining assays. The results show that when transfected alone, IL-17R showed a distribution primarily on the cell surface ( Figure 2A, arrow indicated) . Interestingly, when IL-17RD, which exhibits a vesicle-like punctated staining pattern [29, 30] , was co-expressed, IL-17R distribution changed into a punctated pattern colocalizing with IL-17RD ( Figure 2B ). These results indicate that IL-17RD is able to affect IL-17R localization, suggesting that these two molecules are colocalized and 
IL-17RD mediates IL-17 signaling
To determine whether IL-17RD mediates IL-17 signaling, we used a luciferase reporter driven by the native promoter of mouse 24p3 as described earlier [34] . This reporter plasmid was transfected into mouse embryo fibroblasts (MEFs) together with IL-17RD and/or IL-17R. These experiments demonstrate that overexpression of IL-17RD or IL-17R enhances reporter activity in the absence of ligand. On IL-17 treatment, the IL-17RD-or IL-17R-induced luciferase activity increased ( Figure 3A ). In addition, we found that IL-17RD is homomultimerized in the absence of ligand (data not shown), reminiscent of an earlier report showing that IL-17R self-associates independently of ligand stimulation [35] . These observations 
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npg indicate that forced expression of the receptors results in homodimerization and activation of downstream signaling, which is a known typical feature of type 1 receptors [36] . We also observed that the co-expression of IL-17RD and IL-17R did not lead to any further increase in luciferase activity compared with single receptor expression ( Figure 3A) . A possible explanation for this observation is that additional receptor components, such as IL-17RC [19] , may be limiting. Furthermore, dosedependent assay results showed that increasing amounts of IL-17RD led to higher luciferase activity ( Figure 3B ), supporting the fact that IL-17RD is involved in IL-17 signaling.
To determine which domain of IL-17RD is involved in IL-17 signaling, we co-transfected IL-17RD mutants and the reporter plasmid into MEFs. Luciferase assays demonstrated that IL-17RDDECD retains the ability to mediate IL-17 signaling, whereas IL-17RDDICD fails to do so ( Figure 3C ). As IL-17RDDICD does not deliver the IL-17 signal ( Figure 3C ) but still interacts with IL-17R ( Figure 1C ), we speculated that IL-17RDDICD might function as a dominant-negative form. To test this hypothesis, we carried out luciferase reporter experiments and found that when it was co-expressed with IL-17RD, IL-17RDDICD blocked IL-17RD-mediated IL-17 signaling ( Figure 3C , the last columns in each group). Furthermore, dose-dependent assay results showed that increasing amounts of IL-17RDDICD led to lower activity of the reporter ( Figure 3D ). Interestingly, when IL-17RDDICD was co-expressed with IL-17R, luciferase activity was also inhibited, suggesting that this dominantnegative mutant also suppresses IL-17R-mediated IL-17 signaling ( Figure 3E ). These novel observations indicate that IL-17RD plays an important role in the IL-17 signaling pathway.
IL-17RD physically associates with TRAF6
As the intracellular domain of IL-17RD is pivotal
to its function, we tested whether IL-17RD associates physically with molecules downstream of IL-17R. Given that TRAF6 has been shown to interact with IL-17R and is essential for IL-17 signaling [34, 37] , we co-expressed IL-17RD and TRAF6 in HEK293T cells and examined their potential interaction by immunoprecipitation assays. Our results showed that IL-17RD was co-immunoprecipitated with TRAF6 and vice versa ( Figure 4A and 4B), indicating that IL-17RD and TRAF6 are capable of associating with each other.
Discussion
T H 17 cells are a new type of effector T cells that have been discovered recently. Most current research on T H 17 cells has focused on the mechanisms of T H 17-cell differentiation [38, 39] , whereas relatively little is known about how IL-17 exerts its effects on target tissues. In this study, we show that IL-17RD colocalizes and associates with IL-17R to mediate IL-17 signaling. The precise composition of the IL-17R complex on the cell membrane and how this complex mediates signaling are still not fully understood (see review [16] ); thus, our study provides novel evidence that IL-17R forms a heteromeric complex with IL-17RD. Indeed, it has been reported earlier that IL-17R associates with IL-17RC [19] . More interestingly, we identified that IL-17RD associates not only with IL-17R but also with IL-17RB (see Figure  1C ). These data suggest that IL-17R family members may form different receptor complexes to allow interaction with different ligands. It has been reported that IL-17A and IL-17F form a heterodimer in activated human CD4 + T cells [40] , implying the possibility that different ligands and receptors may be composed at the cell membrane under different physiological conditions.
The fact that IL-17RDDICD is unable to mediate IL-17 signaling but functions as a dominant-negative form ( Figure 3C-E) indicates that the intracellular domain of Figure 4A and 4B). We therefore propose that the IL-17RD intracellular domain interacts with IL-17R and TRAF6 to deliver the downstream signal. Act1 has recently been reported to be an adaptor protein of IL-17R and to mediate immediate receptor downstream signaling [26, 27] ; therefore, it should be very interesting to investigate the interactions and functional relationships among IL-17R, IL-17RD, Act1 and TRAF6, especially in light of our earlier results showing that TRAF6 can mediate IL-17R ubiquitination [34] . IL-17R is ubiquitously expressed; thus, most cells are potential targets of IL-17 action [2] . A major role of IL-17 and T H 17 cells has been described in immunemediated injury models, such as organ-specific autoimmunity in the brain, heart, synovium and intestines, allergic disorders of the lung and skin, and microbial infections of the intestines and the nervous system [5] . The expression pattern of hIL-17RD (hSef) has been examined by northern blotting [41, 42] , and interestingly, the hIL-17RD transcript shows the highest expression in the kidney, followed by the heart, small intestine, colon, skeletal muscle, brain, lung and spleen, but with barely detectable expression in the thymus, liver, placenta and peripheral blood leukocytes. Considering the expression patterns of IL-17R and IL-17RD, and the tissues where IL-17 and T H 17 execute their functions, it is reasonable to suggest that IL-17RD plays a role in IL-17 signaling in cognate tissues.
IL-17RD has recently been shown to inhibit FGF signaling [28] [29] [30] [31] [32] [33] and to facilitate EGF signaling [43] . In this report, we provide data showing that IL-17RD functions in IL-17 signaling, suggesting that IL-17RD has two distinct types of functions. IL-17RD-deficient mice do not show any obvious phenotype related to FGF signaling [44] ; thus, it should be interesting to examine whether these knock-out mice have a phenotype similar to that of IL-17R-deficient mice when challenged with specific pathogens, such as Klebsiella pneumoniae [20] . These types of assays should provide interesting information to further our understanding of the functions of IL-17RD in IL-17 signaling in vivo.
In conclusion, we have shown that IL-17RD colocalizes and associates with IL-17R and mediates IL-17 signaling possibly through its intracellular domain.
Materials and Methods
Plasmid construction
pcDNA3/hIL-17RD (pcDNA3/hSef), pcDNA3.1/Myc-His/hIL-17RD (pcDNA3.1/Myc-His/hSef) and pcDNA3.1/Myc-His/hIL-17R plasmids were described earlier [29, 31, 34] . pcDNA3.1/MycHis/hIL-17RDDICD, an IL-17RD mutant lacking the intracellular domain, was constructed by standard polymerase chain reaction (PCR) mutagenesis using the following primers: forward primer, 5′-tat aag ctt gcc gcc acc atg gcc ccg tgg ctg-3′; reverse primer, 5′-att ctc gag cat cac agt gaa gag cg-3′. pcDNA3.1/Myc-His/sphIL-17RDDECD, used for expression of an IL-17RD mutant lacking the extracellular domain, was constructed with pcDNA3.1/ Myc-His/sp, which was modified from pcDNA3.1/Myc-His as described earlier [29] by inserting a fragment amplified by PCR using the following primers: forward primer, 5′-gca tga att ccc cat cag agc cgt g-3′; reverse primer, 5′-att ctc gag caa agg ggc gac cgc-3′. pcDNA3.1/HA-His/hIL-17R was subcloned from pcDNA3.1/ Myc-His/hIL-17R by double digestion using HindIII and EcoRI restriction endonucleases. PC4-hIL-17RB plasmid was provided by Dr Reinhard Ebner (Human Genome Science, Inc., Rockville, MD) [45] . The coding sequence of IL-17RB was amplified from this construct using the following primers: forward primer, 5′-tag aat tcg cca cca tgt cgc tcg tgc tgc t-3′; reverse primer, 5′-gat ctc gag aag gca agg gga aga gtc t-3′, and then inserted into the HindIII/XhoI sites of pcDNA3.1/Myc-His vector. All of these constructs were confirmed by sequencing. Flag-TRAF6 was provided by Dr Hiroyasu Nakano (Juntendo University, Tokyo, Japan).
Cell culture and transfection
HEK293T cells, COS7 cells, NIH3T3 cells and MEFs were cultured in DMEM containing 10% FBS at 37 °C in 5% CO 2 -containing atmosphere. Transfection was performed by using CalPhos Mammalian Transfection Kit (Clontech) for HEK293T cells, lipofect AMINE2000 (Invitrogen) for COS7 cells and High Efficient Transfection Reagent (Vigorous) for MEFs and NIH3T3 cells according to the manufacturer's protocols. The NIH3T3-IL-17RD stable cell line was established by selection with G418 from the NIH3T3 cells transfected with pcDNA3.1/Myc-His/hSef [29] .
Immunoprecipitation and immunoblotting
Immunoprecipitation from transfected cells was done as described earlier [29] . Anti-Myc (9E10, mouse, Santa Cruz Biotechnology), anti-HA (F-7, mouse, Santa Cruz Biotechnology), antiFlag (M2, mouse, Sigma) and anti-IL-17RD antibodies were used in the experiments. Anti-IL-17RD (anti-Sef) rabbit polyclonal antibody has been described earlier [31] . Anti-IL-17R and anti-IL-17RD antibodies and IL-17 were purchased from R&D Systems.
Luciferase assays
The construction of the 24p3 promoter-luciferase reporter (−1385 to +1) was described earlier [34] . Luciferase assays were carried out in MEFs by co-transfecting 24p3 promoter-luciferase plasmid (2.0 mg for a 24-well plate) and different constructs as indicated. After 24 h, the cells were stimulated with 100 ng/ml IL-17 (17-IL, R&D Systems) for 8 h. Luciferase activity was measured by the Dual Luciferase Assay System (Promega) using Top Count (Packard). The Renilla reniformis luciferase plasmid (pRL-TK, Promega) was co-transfected as an internal control. Experiments were carried out in triplicate for each treatment and the average and standard deviations are shown.
Immunofluorescent staining
COS7 cells were fixed 24 h after transfection, with 4% para-IL-17RD mediates IL-17 signaling 214 npg formaldehyde for 20 min, perforated with 0.3% Triton X-100 for 10 min, and then the cells were blocked with 10% FBS for 50 min, followed by incubation with mouse Myc (9E10, Santa Cruz Biotechnology) and rabbit HA (Y-11, Santa Cruz Biotechnology) antibodies at 4 °C overnight. Cells were incubated with the secondary antibodies, goat anti-mouse IgG/TRITC and goat anti-rabbit IgG/ FITC (Jackson Research Laboratories), for 1 h and counterstained with DAPI for 5 min. Finally, the immunostained cells were visualized with a confocal laser scanning microscope (OLYMPUS BX61).
